26 - 1. Br J Clin Pharmacol. 2008 Apr;65(4):565-72. Epub...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
Sheet1 Page 1 1. Br J Clin Pharmacol. 2008 Apr Perforated peptic ulcer and short-term mortality among tramadol users. Tørring ML, Riis A, Christensen S, Thomsen RW, Jepsen P, Søndergaard J, Sørensen HT. Department of Clinical Epidemiology, Aarhus University Hospital, University of Aarhus, Aarhus, Denmark. mlt@alm.au.dk WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is a strong risk and prognostic factor for peptic ulcer perforation, and alternative analgesics are needed for high-risk patients. * Pain management guidelines propose tramadol as a treatment option for mild-to-moderate pain in patients at high risk of gastrointestinal side-effects, including peptic ulcer disease. * Tramadol may mask symptoms of peptic ulcer complications, yet tramadol's effect on peptic ulcer prognosis is unknown. WHAT THIS STUDY ADDS: * In this population-based study of 1271 patients hospitalized with peptic ulcer perforation, tramadol appeared to increase mortality at least as much as NSAIDs. * Among users of tramadol, alone or in combination with NSAIDs, adjusted 30-day
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 01/10/2010 for the course NSA 1010 taught by Professor Ahobaishi during the Spring '09 term at ND State.

Page1 / 2

26 - 1. Br J Clin Pharmacol. 2008 Apr;65(4):565-72. Epub...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online